INTERCURE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 879.8 ILa | -3.87% |
|
-3.15% | +89.98% |
| May. 01 | InterCure Ltd. Provides Revenue Guidance for the Full Year 2024 | CI |
| May. 01 | InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 388.68 145K | Sales 2023 | 355.55 132K | Capitalization | 211M 78.49B |
|---|---|---|---|---|---|
| Net income 2022 | 44M 16.36B | Net income 2023 | -62M -23.06B | EV / Sales 2022 | 1,473,908 x |
| Net Debt 2022 | 22.37M 8.32B | Net Debt 2023 | 94.35M 35.09B | EV / Sales 2023 | 858,938 x |
| P/E ratio 2022 |
12.2
x | P/E ratio 2023 |
-3.41
x | Employees | 270 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.87% | ||
| 1 week | -3.15% | ||
| Current month | -21.24% | ||
| 1 month | -22.21% | ||
| 3 months | +34.67% | ||
| 6 months | +91.84% | ||
| Current year | +89.98% |
1 week
868.00
927.00
1 month
868.001 250.00
Current year
440.001 346.00
1 year
395.001 346.00
3 years
395.002 635.00
5 years
395.003 999.88
10 years
124.586 317.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 18-09-30 | |
Amos Cohen
DFI | Director of Finance/CFO | 45 | 20-02-29 |
Yisrael Gewirtz
AUD | Comptroller/Controller/Auditor | 47 | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ehud Barak
CHM | Chairman | 81 | 18-08-31 |
| Chief Executive Officer | 53 | 18-09-30 | |
| Director/Board Member | 63 | 20-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.29% | 3 M€ | -35.65% | - | |
| 0.13% | 13 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 879.8 | -3.87% | 114,644 |
| 24-06-10 | 915.2 | +0.59% | 72,652 |
| 24-06-09 | 909.8 | +0.15% | 54,135 |
Delayed Quote TEL AVIV STOCK EXCHANGE, June 13, 2024 at 10:24 am EDT
More quotes
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +89.98% | 108M | |
| +6.17% | 207M | |
| -6.19% | 194M | |
| +23.26% | 160M | |
| -28.57% | 120M | |
| +20.09% | 109M | |
| -60.43% | 82.73M | |
| -11.54% | 76.56M | |
| +100.00% | 60.26M |
- Stock Market
- Equities
- INCR Stock
